CSF3 and neutropenia: Compared with maribavir, neutropenia was associated with greater use of granulocyte-colony stimulating factor (GCSF) with valganciclovir, both during study treatment (valganciclovir, 15.3% of patients; maribavir, 6.2% of patients) and after study treatment discontinuation (valganciclovir, 15.0% of patients; maribavir, 9.2% of patients), and also led to hospitalization more frequently in the valganciclovir arm (6.2% of patients; maribavir, 2.2% of patients).